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Effects of Low Dose Transdermal Scopolamine on Heart Rate
Objectives . We hypothesized that by enhancing parasympa. thetic activity, low dose trans dermal scopolamine would increase heart rate variability after myocardial infarction .
Background. Low heart rate variability is associated with increased mortality after acute myocardial infarction .
Methods. Conventional time domain heart rate variability was measured from U-h loiter recordings of 61 consecutive male patients (mean age 58 :k 10 years, left ventricular ejection fraction 44,7 ± 15,5%) 6 days (median) after acute myocardial infarction . Patients were then randomly assigned to wear one patch of tramidermal scopolamine or a matching placebo patch for 24 h, during which their 24-h heart rate variability was renieasured .
A decrease in heart rate variability measured after acute myocardial infarction predicts subsequent total mortality and arrhythmic events (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . It has been postulated that such decrease in heart rate regulation reflects altered sympathovagal neurocardiac reflex regulation with either increased sympathetic or decreased parasympathetic activity, or both (11) (12) (13) (14) (15) (16) (17) . Although the reduction in hyperadrenergic activity by beta-adrenergic receptor blockade has proved successful in reducing postinfarct morbidity and mortality, the protective effect of vagal stimulation has only recently received increased attention (18, 19) . Direct vagal nerve stimulation in the dog model significantly reduces ischemic injury after coronary artery occlusion (20) and protects nst ventricular fibrillation (21) . Similarly, pharmacologic stimulation of the vagus with low dose atropine (22) , neostigrain: (20 carbachohne, cyclic guanosine monophosphate
MYOCARDIAL INFARCTIO
Results . Compared with placebo, transdermal scopolamine caused a significant increase in time domain treasures of 24-h heart rate variability by 26% to 35% above baseline . Transdermal scopolamine was well tolerated .
Conclusions . Low dose transdermal scopolamine safely increases cardiac parasympathetic activity and short-term heart rate variability after acute myocardial infarction . Whether the effect of transdermal scopolamine on heart rate variability is a reasonable surrogate for improvement of long-term morbidity and mortality requires an appropriately designed investigation .
(I Ant Coil Cardiol 1993 ;22 :1320-6) (24), methacholine and oxotremorine (25) has been shown to reduce ventricular vulnerability in ischemic dog hearts . No corresponding studies have been performed in humans to date . We therefore investigated the feasibility and safety of pharmacologic parasympathetic stimulation in acute myocardial infarction and measured the effects of low dose transdermal scopolamine (26) on heart rate variability, a marker of cardiac parasympathetic activity, in human subjects during the early days after acute myocardial infarction . Previous studies in healthy human subjects have shown that low dose transdermal delivery of scopolamine increased arterial baroreflex sensitivity and heart rate variability, presumably by a parasympathomimetic mode of action (27, 28) .
Whods
Subjects . The study was approved by the Institutional Review Board of Baylor College of Medicine and the Houston Veterans Affairs Medical Center. Sixty-one men, con secutive patients with acute myocardial infarction in the coronary care unit, consented to participate in the study . Patients were enrolled between July 1990 and September 1991 . All subjects had the diagnosis of acute myocardial infarction established independently by their primary physician, based on characteristic symptoms, electrocardiographic (ECG) changes and supranormal elevation in total and serum creatine kinase, MB fraction (CK-MB) levels . By the time of enrollment, the patients were free of chest pair 0735-1097193/$6 .00 JACC Vol. 22, No . 5 November 1, 1993 :1320 TRANSDERMAL SCOPOLAMINIF AFrER MYOCARDIAL INFARCTION and did not require vasopressor or inotropic medications . All patients were in sinus rhythm . While participating in the study, all subjects were under the caie of their primary physician and were receiving standard medical care . Their level of physical activity was as tolerated . Patients with a history of glaucoma and urinary retention were excluded . Study pomaK On enrollment, subjects were randomly assigned to the placebo and scopolamine study arms and underwent a baseline 24-h Holler ambulatory BCC) recording . The study medication (scopolamine or matching placebo) was then administered in a double-blind fashion in the form of a single transdermal therapeutic system (TTS) patch, applied behind the ear, as recommended by the manufacturer (Ciba Consumer Pharmaceuticals) . After wearing the patch for 4 h, an "intervention" 24-h Holler ECG was recorded, during which the patch remained in place . Throughout the study, subjects were observed and questioned for adverse effects and underwent continuous cardiac rhythm monitoring . Clinical information was obtained through patient interview and review of the medical record . Left ventricular ejection fraction was calculated by echocardiography (51%), cardiac catheterization (46%) or by gated wall motion study (3%) during the same hospital period . low recording and processing. All Holier tapes were recorded on Marquette Electronics hic . analog cassette dualchannel recorders that include a timing track . Tapes were analyzed by a single experienced technician on a Marquette Electronics 8000 Holter research system (analog/digital 128 Hz) . Beat by beat annotation of normal (sinus) beats, nonsinus beats and artifact was performed during visual scanning of the data. Annotated event files were generated using the QRSDK program provided by Marquette Electronics and were transmitted to a VAX computer (Digital Equipment Corp.) for further analysis . Based on the original beat annotation code, secondary files containing only normal to normal interbeat intervals were generated . Postectopic normal to normal intervals were included in the analysis .
Heart rate variability measures. The following conventional time domain indexes of heart rate variability were calculated for the entire Holler recording : 1) global standard deviation (SD) of all normal to normal intervals (1,2,10,29,30) ; 2) mean value of the SDs of consecutive 5-min segments (10, 29, 30) ; 3) SD of the mean values of consecutive 5-min segments (29, 30) ; and 4) root-mean-squared successive normal to normal differences (13) . The latter was computed only when normal beats occurred in groups of three or more .
As a consequence of signal loss, excessive ectopic activity or noise, it was not possible to analyze all 5-min segments of every recording . An arbitrary lower bound of 10 was placed on the number of normal to normal intervals required for acceptability of a 5-min segment . However, the overwhelming majority of segments contained >100 normal to normal intervals . Using the mean heart rate over the entire recording, an estimated number of normal to normal intervals per 5-min segment were calculated . For patients in the scopolamine group, the average percent of expected inter-vats in analyzed segments was 87 .7%, whereas for the placebo group, the average number of intervals analyzed per 5-min segment was 91 .7% of the expected number . Four scopolamine tapes (three patients) had ratios <50%, but no placebo group patient had a ratio below this level .
Statistical analysis . Between-group data comparisons were performed using the Mann-Whitney test and, where appropriate, the two-sided Fisher exact test . Spearman rank correlation coefficients (r,) and the corresponding test of significance were used to nonparametrically assess relation between variables . Linear regression was used to assess treatment-covariate interactions (BMDP Statistical Software, Inc .) . Nonparametric statistical methods were used when possible because the variables generally did not exhibit a normal distribution . Statistical significance was accepted if p < 0 .05 . No adjustment for multiple comparisons was made . Because of the small group size, we elected not to perform an analysis of covariance with regard to baseline clinical variables and equally did not adjust our results for concomitant therapy .
Results
Clinical characteristics . Sixty-one consecutive male patients (mean age 58 ± 10 years, left ventricular ejection fraction 44 .7 ± 15 .5%) were enrolled 6 days (median) after acute myocardial infarction . Clinical data of the scopolamine and placebo patient groups are summarized in Table 1 . Both groups were comparable with respect to age, previous cardiac history, myocardial infarction location, presence of Q waves on the ECG and serum creatine kinase (CK) level (all p > 0 .1) . Left ventricular ejection fraction was marginally lower in the scopolamine group (p = 0 .06) . Seventy-five percent of the patients underwent coronary arteriograpby . Single-vessel coronary artery disease was present in 35% and 29% of the scopolamine and placebo group patients, respectively . Two-vessel disease was found in 30% and 25% and three-vessel disease in 35% and 46% of the scopolamine and placebo group patients, respectively (all p > 0 .1) . Four patients in the scopolamine group used digitalis preparations in contrast to none of the patients receiving placebo (p = 0 .52) . Nonstudy medications were not changed between baseline and intervention .
Heart rate variability after acute myocardial infarction . Of 61 randomized study subjects, 58 completed both Holter recordings. One patient (randomized to the scopolamine group) completed only a baseline recording because of early discharge from the hospital . In two scopolamine group patients, the baseline Holter tape could not be analyzed because of technical difficulty with the data acquisition . There was no difference between the placebo and scopolamine groups with regard to the time interval between myocardial infarction and the baseline and intervention Holier recordings, respectively ( Table 2) .
Baseline heart rate variability did not differ between the scopolamine and placebo groups (all p > 0 .05) ( seline heart rate variability correlated with left ventricular ejection fraction (r5 = 0 .33 -0 .49, all p < 0 .02) but was not related to peak serum CIA level, CK-ME fraction, history of thrombolysis, presence of a Q wave on the initial ECG, infarct location or history of previous myocardial infarction (all p > 0, 1). Although 33 patients who received beta- various heart rate variability variables (r, = 0 .48 -0.95, all p < 0 .0001) and between mean heart rate and heart rate variability (I, , = 0.50 -0.73, all p < 0 .0001) .
Effect of transdermall scopolamine on heart rate variability after acute myocardial infarction . Table 2 compares heart rate variability for the scopolamine and placebo groups at baseline (6 .3 ± 2 .9 days after myocardial infarction) and after intervention (9 .5 ± 8 .2 days) . In all but five subjects, heart rate variability increased with scopolamine . Global SD increased by a median value of 34%, the mean value of the SDs of consecutive 5-min segments by 35%, the SD of consecutive 5-min mean values by 28% and the root-meansquared successive normal to normal interval difference by 26% . The respective changes in the placebo group were 8%, 3%, 6% and -3% (all p < 0 .01) ( Table 3 ) . The relative difference between scopolamine and placebo was highly significant for all four variables of heart rate variability . Figure 1 shows the individual changes in global SD for all study subjects before and after receiving placebo or scopolamine, respectively . The effects of scopolamine on heart rate were smaller. The mean normal to normal interval increased by 5 .9%, whereas the corresponding change in the placebo group was -1 .4% (p = 0 .04) . There was a strong correlation among the indexes of heart rate variability and heart rate, with the following exceptions : the mean normal to normal interval and SD of consecutive 5-min segments and the root-mean-squared successive difference and SD of consecutive 5-min mean values, respectively (Table 4 ) . In light of this apparent relation between changes in heart rate variability and changes in heart rate, heart rate variability variables were normalized for heart rate by dividing each individual value by the corresponding mean normal to normal interval . After this normalization, the effect of scopolamine (compared with placebo) remained significant for the mean value of the SDs of consecutive 5-min segments (p < 0 .0001), for the SD of consecutive 5-min mean values (p = 0 .04) and for the root-mean-squared successive normal to normal interval difference (p = 0 .002) . The effect of scopolamine on the global SD was no longer apparent (p = 0 .96) .
Treatment-covariate interactions . The relation of clinical variables at baseline to the treatment effect (scopolamine compared with placebo) on heart rate variability was examined . Because of the study size, the power in detecting interaction effects was low . There was no uniform relation between left ventricular ejection fraction, when dichotomized at 40%, and treatment effect on heart rate variability (global SD, p = 0 .05 ; mean value of the SDs of consecutive 5-min segments, p = 0 .23 ; SD of consecutive 5-min mean SD (ms) 0 .60 0 .90 0.39 (1) < 0 .0001) (p < 0 .0001) (p = 6.0620) MNSD (ms) 0 .36 0.81 (p = 0,0002) (p < 0-Wol) SDMN (ms) 0.25 (p -10%64)
Values presented are Spearman rank correlation coefficients with corresponding p values . Abbreviations as in Table 2 . values, p = 0.06 ; root-mean-squared successive normal to normal interval difference, p -0 .57) or when ejection fraction was examined as a continuous variable (global SD, p = 0 .08 ; mean value of the SDs of consecutive 5-min segments, p -0.30 ; SD of consecutive 5-min mean values, p = 0,04; root-mean-squared successive normal to normal interval difference, p = 1 .00) . Baseline global SD, dichotomized at 50 ms, did not predict heart rate variability response to treatment (all p > 0.2) . Myocardial infarction location, the presence of a Q wave on the ECG, peak serum CK level, history of thrombolysis and history of a previous myocardial infarction were not related to treatment effect on heart rate variability (all p > 0 .05) . Subjects receiving beta-blockers showed a heart rate variability response to scopolamine (compared with placebo) similar to that of subjects not receiving beta-blockers (all p > 0.2) . The heart rate variability measures (at baseline and after patch) of the four subjects randomly assigned to receive scopolamine who were also receiving digoxin, were not different from those of the subjects randomly assigned to receive scopolamine who were not taking digoxin (p > 0 .26).
Ad"rft eflects of kansdamal scopolamine. The overall incidence of adverse effects was low . No patches were removed before termination of the study . Table 5 lists the subjective adverse effects during the study . Five patients receiving scopolamine experienced dry mouth compared with no patients receiving placebo (p = 0,024) . During the study all patients were hemodynamically stable, and no affhYthmias were observed . There was no exacerbation of Ona, and no reinfarction occurred . There were no deaths .
ENSUCMUMSSdian
This randomized, placebo-controlled clinical trial describes the efficacy and safety of low dose transdermal scopolamine in patients with acute myocardial infarction in whom it caused a significant increase in heart rate variability . The uniform increase in all four heart rate variability variables of between 26% (root-mean-squared successive normal to normal interval difference) and 35% (mean value of the SD of consecutive 5-min segments) is consistent with a previous report of transdermal scopolamine in young, healthy volunteers, in whom an effect on short-term heart rate variability of similar magnitude was observed (28) .
Recent reports (13) (14) (15) 31, 32) have established a strong correlation between vagal neural activity and both time and frequency domain indexes of heart rate variability . Our findings of increased time domain variables of heart rate variability by low dose scopolamine in myocardial infarction are therefore consistent with a parasympathomimetic mode of action. Similar to atropine, scopolamine exhibits opposing, dose-dependent effects. When used in high doses, scopolamine blocks peripheral parasympathetic activity, whereas at low doses, scopolamine exerts a paradoxic parasympathomimetic effect that is purportedly mediated by the central nervous system (46428, (33) (34) (35) (36) (37) (38) . Accordingly, by providing continuous percutaneous low dose drug delivery, the transdcrmal scopolamine therapeutic system (Transderm Scop) has been shown to enhance both arterial baroreflex sensitivity (27) and time and frequency domain indexes of short-term heart rate variability (28) in healthy adults .
Previous studies (1, 39) have demonstrated a close interdependence of heart rate and heart rate variability . Although the beneficial effect of beta-blockers appears to be related to both a slowing of the heart rate and an increase in heart rate variability (40-42), the cardioprotective effect of parasympathetic stimulation may be less dependent on heart rate reduction (1, 12, 24, 25) . Therefore, the rather modest bradycardia induced by scopolamine in this study does not necessarily preclude a potential beneficial clinical effect. Patients receiving beta-blockers experienced an increase in heart rate variability similar to that of subjects not receiving betablockers . Scopolamine increased heart rate variability in subjects with left ventricular ejection fraction ranging from 12% to 66% and with baseline heart rate variability (global SD) ranging from 22 to 132 ms.
It is unlikely that the study outcome was affected by medication use because although the majority of cardiotropic medications used by our patients affect heart rate variability (41) (42) (43) (44) (45) (46) , the treatment and control groups were comparable with respect to their use . Although four subjects randomized to receive scopolamine were also receiving digoxin, an agent with known parasympathetic activity, their heart rate variability response to scopolamine was similar to that of the other subjects receiving scopolamine . Both groups were sirr ilar with respect to clinical variables known to affect heart rate variability, notably age (14) , extent of coronary artery disease (47, 48) , prevalence of heart failure (49, 50) and of diabetes mellitus (51) . Our findings are consistent with a previous report of a beneficial antiarrhythmic and hemodynamic effect of paren-temWl scopolamine after acute myocardial infarction (52) and with previous smaller studies on the effects of transdermal scopolamine after acute myocardial infarction (53) (54) (55) .
The present study focused exclusively on conventional (time domain) statistics because they have been widely applied and are being implemented in some commercial ambulatory ECG analysis systems . The application of spectral analysis to loiter data remains problematic because of unresolved questions relative to optimal data set size, nonstationarity, the type of algorithm and the presence of ectopic activity (15, 56, 57) , Finally, a strong correlation has been demonstrated between the 24-h root-mean-squared successive normal to normal interval difference and the high frequency component of the interbeat interval power spectrum, which is almost exclusively parasympathetically mediated (13) .
Study limitations. Our trial was not designed to assess the morbidity and mortality effects of transdermal scopolamine . Also, although we demonstrated a significant short-term effect of scopolamine on cardiac parasympathetic activity, this study was not designed to evaluate the long-term efficacy and safety of transdermal scopolamine . In addition, given the relatively low risk profile of our patient group, we cannot describe its effects on patients who have a larger infarct size and a lower left ventricular ejection fraction .
Conclusions . Decreased heart rate variability, reflecting autonomic neurocardiac regulatory dysfunction, is associated with increased mortality after acute myocardial infarction . We demonstrated that low dose transdermal scopolamine increases heart rate variability with no observed serious short-term toxicity after acute myocardial infarction . Whether the effect of transdermal scopolamine on heart rate variability is a reasonable surrogate for lessening of longterm morbidity and mortality requires an appropriately designed investigation .
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